PMV Pharmaceuticals News

PMV Pharmaceuticals to Participate at Upcoming Investor Conferences in June

PRINCETON, N.J., May 30, 2024 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (NASDAQ:PMVP), a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting

GlobeNewswireMay 30 19:00

Buy Rating on PMV Pharmaceuticals: Strategic Partnerships and Promising Clinical Pipeline Underpin Positive Outlook

TipRanksMay 30 18:35

Foundation Medicine and PMV Pharma Announce Collaboration to Develop Companion Diagnostic for Rezatapopt, a First-In-Class, Investigational, Selective P53 Y220C Reactivator

BOSTON and PRINCETON, N.J., May 29, 2024 (GLOBE NEWSWIRE) -- Foundation Medicine, Inc. and PMV Pharmaceuticals, Inc. (NASDAQ:PMVP, "PMV Pharma")) today announced a partnership to develop Foundation Medicine's

GlobeNewswireMay 29 19:00

Analysts Offer Insights on Healthcare Companies: PMV Pharmaceuticals (PMVP) and Phathom Pharmaceuticals (PHAT)

TipRanksMay 17 20:50

PMV Pharmaceuticals Initiated at Buy by Craig-Hallum

PMV Pharmaceuticals Initiated at Buy by Craig-Hallum

Dow JonesMay 14 00:30

Craig-Hallum Initiates Coverage On PMV Pharma With Buy Rating, Announces Price Target of $6

Craig-Hallum analyst Albert Lowe initiates coverage on PMV Pharma with a Buy rating and announces Price Target of $6.

Analyst UpgradesMay 14 00:20

PMV Pharma Q1 EPS $(0.30) Beats $(0.37) Estimate

PMV Pharma (NASDAQ:PMVP) reported quarterly losses of $(0.30) per share which beat the analyst consensus estimate of $(0.37) by 18.92 percent. This is a 28.57 percent increase over losses of $(0.42) p

BenzingaMay 9 20:52

PMV Pharmaceuticals | 10-Q: Quarterly report

SEC announcementMay 9 20:02 · Announcements

PMV Pharmaceuticals 1Q Loss/Shr 30c >PMVP

PMV Pharmaceuticals 1Q Loss/Shr 30c >PMVP

Dow JonesMay 9 20:00

PMV Pharmaceuticals Initiated at Buy by Jefferies

PMV Pharmaceuticals Initiated at Buy by Jefferies

Dow JonesApr 12 21:31

Jefferies Starts PMV Pharmaceuticals With Buy Rating, $5 Price Target

Jefferies Starts PMV Pharmaceuticals With Buy Rating, $5 Price Target.

MT NewswiresApr 12 20:03

PMV Pharmaceuticals Announces First Patient Dosed in Global Tumor-Agnostic Phase 2 PYNNACLE Trial for Rezatapopt in TP53 Y220C-Positive Solid Tumors

Rezatapopt is a first-in-class precision oncology investigational therapy for patients with advanced solid tumors with a TP53 Y220C mutation and KRAS wild-type (WT)First patient dosed in Phase 2 porti

GlobeNewswireMar 27 20:00

Oppenheimer Remains a Hold on PMV Pharmaceuticals (PMVP)

TipRanksMar 19 19:55

PMV Pharmaceuticals PYNNACLE Phase I Data of Rezatapopt in Advanced Ovarian Cancer Featured in Late-Breaking Oral Presentation at 2024 SGO Annual Meeting on Women's Cancer

Phase 1 analysis from the PYNNACLE Phase 1/2 study showed promising efficacy of rezatapopt (PC14586) in heavily pre-treated patients with advanced ovarian cancer harboring a TP53 Y220C mutation featured in a

GlobeNewswireMar 19 04:01

Big Pharma Patent Cliffs Seen Fueling Oncology M&A This Year

Seeking AlphaMar 11 01:08

HC Wainwright & Co. Reiterates Buy on PMV Pharma, Maintains $5 Price Target

HC Wainwright & Co. analyst Robert Burns reiterates PMV Pharma with a Buy and maintains $5 price target.

Analyst UpgradesMar 7 20:11

PMV Pharmaceuticals: Buy Rating Affirmed Amid Strong Financials and Promising Clinical Prospects

TipRanksMar 7 19:27

PMV Pharmaceuticals Inc (PMVP) Reports Full Year 2023 Financial Results

Yahoo FinanceMar 1 23:21

Oppenheimer Keeps Their Hold Rating on PMV Pharmaceuticals (PMVP)

TipRanksMar 1 20:48

TD Cowen Reaffirms Their Buy Rating on PMV Pharmaceuticals (PMVP)

TipRanksMar 1 07:35